Haseki TIp Bulteni-Medical Bulletin of Haseki最新文献

英文中文

Predictive Value of the Hematopoietic Stem Cell Transplantation - Comorbidity Index for Overall Survival in Patients with Multiple Myeloma 造血干细胞移植的预测价值-多发性骨髓瘤患者总生存的共病指数

IF 0.3 Q3 MEDICINE, GENERAL & INTERNAL

Haseki TIp Bulteni-Medical Bulletin of Haseki

Pub Date : 2022-11-01 DOI: 10.4274/haseki.galenos.2022.8668

T. Elibol, Osman Kara

引用次数: 0

Relationship Between Smell Disorders and Pulmonary Involvement in COVID-19 COVID-19患者嗅觉障碍与肺部受累的关系

IF 0.3 Q3 MEDICINE, GENERAL & INTERNAL

Haseki TIp Bulteni-Medical Bulletin of Haseki

Pub Date : 2022-11-01 DOI: 10.4274/haseki.galenos.2022.8651

D. Çakan, Semih Uşaklıoğlu

Aim: Some symptoms of coronavirus disease-2019 (COVID-19) are more common in patients without pulmonary involvement and in patients with a good prognosis. Although it is known that smelling disorders are more common in patients with a good prognosis, their relationship with pulmonary involvement is unknown. This study ianvestigated the relationship between smell disorders and pulmonary involvement in COVID-19. Method(s): This cross-sectional study was conducted between May 2022 and July 2022 and included 60 COVID-19 patients with pulmonary involvement and 60 COVID-19 patients without pulmonary involvement. Phone-call interviews were performed with all patients 1 month after the diagnosis of COVID-19 and their sense of smell was questioned with a questionnaire. The prevalence of smell disorders, type and severity of smell disorders were questioned, and participants were asked to grade their answers from 0 to 10. Result(s): In 58 (48.3%) of the patients, smell disorders were found to be present. Hyposmia was detected in 35 (60.34%), and anosmia was detected in 23 (39.66%) of these patients. Smell disorder was present in 20 (33.3%) patients with pulmonary involvement and in 38 (63.3%) patients without pulmonary involvement. The prevalence of smell disorders was significantly higher in patients without pulmonary involvement (p=0.001). Hyposmia in 15 patients (25%) and anosmia in 5 patients (8.3%) were found in patients with pulmonary involvement. Hyposmia in 20 patients (33.3%) and anosmia in 5 patients (8.3%) were found in patients without pulmonary involvement. The prevalence of anosmia was significantly higher in patients without pulmonary involvement (p=0.003). The smell disorders were significantly more severe in patients without pulmonary involvement (p=0.042). Conclusion(s): Smell disorders are seen more frequently and more severely in patients without pulmonary involvement due to COVID-19 than in patients with pulmonary involvement. Copyright © 2022 by The Medical Bulletin of Istanbul Haseki Training and Research Hospital The Medical Bulletin of Haseki published by Galenos Yayinevi.

目的:新型冠状病毒病-2019 (COVID-19)的一些症状在未累及肺部的患者和预后良好的患者中更为常见。虽然已知嗅觉障碍在预后良好的患者中更为常见，但其与肺部受累的关系尚不清楚。本研究探讨了COVID-19患者嗅觉障碍与肺部受累的关系。方法:本横断面研究于2022年5月至2022年7月期间进行，包括60例肺部受累的COVID-19患者和60例未肺部受累的COVID-19患者。在确诊后1个月对所有患者进行电话访谈，并通过问卷调查对其嗅觉进行调查。研究人员询问了嗅觉障碍的患病率、嗅觉障碍的类型和严重程度，并要求参与者从0到10给他们的答案打分。结果:58例(48.3%)患者存在嗅觉障碍。其中35例(60.34%)出现低嗅觉，23例(39.66%)出现嗅觉缺失。20例(33.3%)肺部受累患者存在嗅觉障碍，38例(63.3%)无肺部受累患者存在嗅觉障碍。在没有肺部受累的患者中，嗅觉障碍的患病率明显更高(p=0.001)。肺部受累患者出现15例(25%)低通气，5例(8.3%)嗅觉缺失。无肺受累的患者有20例(33.3%)低通气，5例(8.3%)嗅觉缺失。没有肺部受累的患者嗅觉缺失的患病率明显更高(p=0.003)。未累及肺部的患者嗅觉障碍更为严重(p=0.042)。结论:与肺部受累患者相比，COVID-19无肺部受累患者嗅觉障碍出现的频率和严重程度更高。伊斯坦布尔Haseki培训和研究医院医学公报版权所有©2022。Galenos Yayinevi出版的Haseki医学公报。

{"title":"Relationship Between Smell Disorders and Pulmonary Involvement in COVID-19","authors":"D. Çakan, Semih Uşaklıoğlu","doi":"10.4274/haseki.galenos.2022.8651","DOIUrl":"https://doi.org/10.4274/haseki.galenos.2022.8651","url":null,"abstract":"Aim: Some symptoms of coronavirus disease-2019 (COVID-19) are more common in patients without pulmonary involvement and in patients with a good prognosis. Although it is known that smelling disorders are more common in patients with a good prognosis, their relationship with pulmonary involvement is unknown. This study ianvestigated the relationship between smell disorders and pulmonary involvement in COVID-19. Method(s): This cross-sectional study was conducted between May 2022 and July 2022 and included 60 COVID-19 patients with pulmonary involvement and 60 COVID-19 patients without pulmonary involvement. Phone-call interviews were performed with all patients 1 month after the diagnosis of COVID-19 and their sense of smell was questioned with a questionnaire. The prevalence of smell disorders, type and severity of smell disorders were questioned, and participants were asked to grade their answers from 0 to 10. Result(s): In 58 (48.3%) of the patients, smell disorders were found to be present. Hyposmia was detected in 35 (60.34%), and anosmia was detected in 23 (39.66%) of these patients. Smell disorder was present in 20 (33.3%) patients with pulmonary involvement and in 38 (63.3%) patients without pulmonary involvement. The prevalence of smell disorders was significantly higher in patients without pulmonary involvement (p=0.001). Hyposmia in 15 patients (25%) and anosmia in 5 patients (8.3%) were found in patients with pulmonary involvement. Hyposmia in 20 patients (33.3%) and anosmia in 5 patients (8.3%) were found in patients without pulmonary involvement. The prevalence of anosmia was significantly higher in patients without pulmonary involvement (p=0.003). The smell disorders were significantly more severe in patients without pulmonary involvement (p=0.042). Conclusion(s): Smell disorders are seen more frequently and more severely in patients without pulmonary involvement due to COVID-19 than in patients with pulmonary involvement. Copyright © 2022 by The Medical Bulletin of Istanbul Haseki Training and Research Hospital The Medical Bulletin of Haseki published by Galenos Yayinevi.","PeriodicalId":42416,"journal":{"name":"Haseki TIp Bulteni-Medical Bulletin of Haseki","volume":"41 1","pages":""},"PeriodicalIF":0.3,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86959052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Anesthesia Management in Cesarian Section in Pregnant Patients with COVID-19 Diagnoses 诊断为COVID-19的妊娠患者剖宫产的麻醉管理

IF 0.3 Q3 MEDICINE, GENERAL & INTERNAL

Haseki TIp Bulteni-Medical Bulletin of Haseki

Pub Date : 2022-11-01 DOI: 10.4274/haseki.galenos.2022.8721

Necmiye Ay, D. Akyol, Gizem Nur Koyan Karadeniz, M. Çelik, Funda Gumus Ozcan

Aim: The recommendation to avoid general anesthesia in pregnant women with coronavirus disease-2019 (COVID-19) and to use neuraxial blockade techniques, if possible, has not changed over time. On the other hand, general anesthesia also has to be applied to some patients in clinical practice. In this study, we evaluated anesthesia management, maternal outcomes, and clinical course in pregnant women with COVID-19 who delivered by cesarean section. Method(s): One hundred and seven pregnant women with COVID-19 who underwent cesarean sections between October 2020 and April 2021 were included in the study. Anesthesia methods, presenting symptoms, comorbidities, laboratory test results, and radiological data at admission, length of hospital stay, intensive care unit admissions, and mortality rates were retrospectively analyzed. Result(s): Out of 107 pregnant women, 85 underwent cesarean surgery under spinal anesthesia and 22 under general anesthesia. Forty patients (37%) had at least one symptom, whereas sixty-seven (63%) had no symptoms at all. Fifty percent of symptomatic and only 6% of asymptomatic pregnant women were admitted to the intensive care unit, and there was a significant difference between them. Mortality was 30% in symptomatic patients and only 1% in asymptomatic patients, and the difference in mortality was significant (p<0.05). Conclusion(s): Since the risk of intensive care and mortality is higher, particularly in symptomatic pregnant women with COVID-19, these patients should be evaluated, operated and followed up by experienced teams. Copyright © 2022 by The Medical Bulletin of Istanbul Haseki Training and Research Hospital The Medical Bulletin of Haseki published by Galenos Yayinevi.

目的:建议对感染冠状病毒病-2019 (COVID-19)的孕妇避免全身麻醉，并在可能的情况下使用神经轴阻断技术，这一建议并未随着时间的推移而改变。另一方面，在临床实践中，一些患者也不得不进行全身麻醉。在这项研究中，我们评估了剖宫产分娩的COVID-19孕妇的麻醉管理、产妇结局和临床病程。方法:研究纳入了107名在2020年10月至2021年4月期间接受剖宫产手术的COVID-19孕妇。回顾性分析麻醉方法、表现症状、合并症、实验室检查结果、入院时放射学资料、住院时间、重症监护病房入院和死亡率。结果:107例孕妇中，腰麻下行剖宫产术85例，全身麻醉下行剖宫产术22例。40名患者(37%)至少有一种症状，而67名患者(63%)完全没有症状。50%的有症状孕妇和6%的无症状孕妇进入重症监护病房，两者之间存在显著差异。有症状患者的死亡率为30%，无症状患者的死亡率仅为1%，差异有统计学意义(p<0.05)。结论:由于重症监护的风险和死亡率较高，特别是有症状的COVID-19孕妇，应由经验丰富的团队对这些患者进行评估、手术和随访。伊斯坦布尔Haseki培训和研究医院医学公报版权所有©2022。Galenos Yayinevi出版的Haseki医学公报。

{"title":"Anesthesia Management in Cesarian Section in Pregnant Patients with COVID-19 Diagnoses","authors":"Necmiye Ay, D. Akyol, Gizem Nur Koyan Karadeniz, M. Çelik, Funda Gumus Ozcan","doi":"10.4274/haseki.galenos.2022.8721","DOIUrl":"https://doi.org/10.4274/haseki.galenos.2022.8721","url":null,"abstract":"Aim: The recommendation to avoid general anesthesia in pregnant women with coronavirus disease-2019 (COVID-19) and to use neuraxial blockade techniques, if possible, has not changed over time. On the other hand, general anesthesia also has to be applied to some patients in clinical practice. In this study, we evaluated anesthesia management, maternal outcomes, and clinical course in pregnant women with COVID-19 who delivered by cesarean section. Method(s): One hundred and seven pregnant women with COVID-19 who underwent cesarean sections between October 2020 and April 2021 were included in the study. Anesthesia methods, presenting symptoms, comorbidities, laboratory test results, and radiological data at admission, length of hospital stay, intensive care unit admissions, and mortality rates were retrospectively analyzed. Result(s): Out of 107 pregnant women, 85 underwent cesarean surgery under spinal anesthesia and 22 under general anesthesia. Forty patients (37%) had at least one symptom, whereas sixty-seven (63%) had no symptoms at all. Fifty percent of symptomatic and only 6% of asymptomatic pregnant women were admitted to the intensive care unit, and there was a significant difference between them. Mortality was 30% in symptomatic patients and only 1% in asymptomatic patients, and the difference in mortality was significant (p<0.05). Conclusion(s): Since the risk of intensive care and mortality is higher, particularly in symptomatic pregnant women with COVID-19, these patients should be evaluated, operated and followed up by experienced teams. Copyright © 2022 by The Medical Bulletin of Istanbul Haseki Training and Research Hospital The Medical Bulletin of Haseki published by Galenos Yayinevi.","PeriodicalId":42416,"journal":{"name":"Haseki TIp Bulteni-Medical Bulletin of Haseki","volume":"60 1","pages":""},"PeriodicalIF":0.3,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72755341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Risk Factors and Predictors of 1-year Overall Mortality in Patients with COVID-19 COVID-19患者1年总死亡率的危险因素和预测因素

IF 0.3 Q3 MEDICINE, GENERAL & INTERNAL

Haseki TIp Bulteni-Medical Bulletin of Haseki

Pub Date : 2022-11-01 DOI: 10.4274/haseki.galenos.2022.8501

S. Surme, G. Tuncer, O. Bayramlar, Hindirin Takak, B. Copur, M. Yazla, E. Zerdali, İnci Yılmaz Nakir, G. Sengoz, F. Pehlivanoğlu

Aim: To date, limited data exists on 1-year mortality and associated factors in patients with coronavirus diseases-2019 (COVID-19). We determined risk factors and predictors of 1-year mortality. Method(s): In this retrospective and single-center study, hospitalized patients with COVID-19 were enrolled between March 11 and March 11, 2020. The primary outcome was 1-year all-cause mortality after discharge from the hospital. Secondary outcomes were the risk factors and predictors of 1-year mortality. A comparative analysis was applied to patients who died after recovering from acute COVID-19 and patients who survived. Result(s): A total of 567 patients were analyzed. The 1-year mortality occurred in 18 (3.2%) patients. Older age (p=0.001), chronic obstructive pulmonary disease (p=0.001), chronic artery disease (p=0.001), chronic renal failure (p=0.001), presence of pleural fluid (p=0.001), high levels of leukocyte (p=0.001), neutrophil (p=0.001), monocyte (p=0.026), C-reactive protein (p=0.042), procalcitonin (p=0.004), urea (p=0.001), creatinine (p=0.001), troponin (p=0.001), lactate dehydrogenase (p=0.019), potassium (p=0.003), and a low level of alanine aminotransferase (p=0.001) at the first admission were associated with increased long-term mortality. Additionally, the need for intensive care unit (ICU) admission (p=0.007) and invasive ventilation (p=0.019) during the hospital stay for COVID-19 were associated with increased 1-year mortality. Conclusion(s): This study suggests that age, underlying diseases, pleural fluid, certain laboratory parameters, and ICU care are somewhat associated with 1-year mortality. Copyright © 2022 by The Medical Bulletin of Istanbul Haseki Training and Research Hospital The Medical Bulletin of Haseki published by Galenos Yayinevi.

迄今为止，关于2019冠状病毒病(COVID-19)患者1年死亡率及相关因素的数据有限。我们确定了1年死亡率的危险因素和预测因素。方法:在这项回顾性单中心研究中，纳入2020年3月11日至3月11日住院的COVID-19患者。主要结局是出院后1年的全因死亡率。次要结局是1年死亡率的危险因素和预测因素。对比分析了急性COVID-19康复后死亡的患者和存活的患者。结果:共分析567例患者。1年死亡率为18例(3.2%)。老年(p=0.001)、慢性阻塞性肺病(p=0.001)、慢性动脉疾病(p=0.001)、慢性肾衰竭(p=0.001)、胸膜积液(p=0.001)、白细胞(p=0.001)、中性粒细胞(p=0.001)、单核细胞(p=0.026)、c反应蛋白(p=0.042)、降钙素原(p=0.004)、尿素(p=0.001)、肌酐(p=0.001)、肌钙蛋白(p=0.001)、乳酸脱氢酶(p=0.019)、钾(p=0.003)、首次入院时低水平的丙氨酸转氨酶(p=0.001)与长期死亡率增加相关。此外，因COVID-19住院期间需要重症监护病房(ICU) (p=0.007)和有创通气(p=0.019)与1年死亡率增加相关。结论:本研究提示年龄、基础疾病、胸腔积液、某些实验室参数和ICU护理与1年死亡率有一定关系。伊斯坦布尔Haseki培训和研究医院医学公报版权所有©2022。Galenos Yayinevi出版的Haseki医学公报。

{"title":"Risk Factors and Predictors of 1-year Overall Mortality in Patients with COVID-19","authors":"S. Surme, G. Tuncer, O. Bayramlar, Hindirin Takak, B. Copur, M. Yazla, E. Zerdali, İnci Yılmaz Nakir, G. Sengoz, F. Pehlivanoğlu","doi":"10.4274/haseki.galenos.2022.8501","DOIUrl":"https://doi.org/10.4274/haseki.galenos.2022.8501","url":null,"abstract":"Aim: To date, limited data exists on 1-year mortality and associated factors in patients with coronavirus diseases-2019 (COVID-19). We determined risk factors and predictors of 1-year mortality. Method(s): In this retrospective and single-center study, hospitalized patients with COVID-19 were enrolled between March 11 and March 11, 2020. The primary outcome was 1-year all-cause mortality after discharge from the hospital. Secondary outcomes were the risk factors and predictors of 1-year mortality. A comparative analysis was applied to patients who died after recovering from acute COVID-19 and patients who survived. Result(s): A total of 567 patients were analyzed. The 1-year mortality occurred in 18 (3.2%) patients. Older age (p=0.001), chronic obstructive pulmonary disease (p=0.001), chronic artery disease (p=0.001), chronic renal failure (p=0.001), presence of pleural fluid (p=0.001), high levels of leukocyte (p=0.001), neutrophil (p=0.001), monocyte (p=0.026), C-reactive protein (p=0.042), procalcitonin (p=0.004), urea (p=0.001), creatinine (p=0.001), troponin (p=0.001), lactate dehydrogenase (p=0.019), potassium (p=0.003), and a low level of alanine aminotransferase (p=0.001) at the first admission were associated with increased long-term mortality. Additionally, the need for intensive care unit (ICU) admission (p=0.007) and invasive ventilation (p=0.019) during the hospital stay for COVID-19 were associated with increased 1-year mortality. Conclusion(s): This study suggests that age, underlying diseases, pleural fluid, certain laboratory parameters, and ICU care are somewhat associated with 1-year mortality. Copyright © 2022 by The Medical Bulletin of Istanbul Haseki Training and Research Hospital The Medical Bulletin of Haseki published by Galenos Yayinevi.","PeriodicalId":42416,"journal":{"name":"Haseki TIp Bulteni-Medical Bulletin of Haseki","volume":"76 1","pages":""},"PeriodicalIF":0.3,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80771812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical Characteristics of COVID-19 in Active or Previously Treated Tuberculosis Patients in Turkey 土耳其活动性或既往治疗过的结核病患者中COVID-19的临床特征

IF 0.3 Q3 MEDICINE, GENERAL & INTERNAL

Haseki TIp Bulteni-Medical Bulletin of Haseki

Pub Date : 2022-11-01 DOI: 10.4274/haseki.galenos.2022.8327

Sumeyra Kayali, Fatma Nur Karaçorlu, Mustafa YILMAZ, Zulal Aşçı Toraman, E. Pirinççi

Aim: There is limited literature on coronavirus disease-2019 (COVID-19) and tuberculosis (TB) coinfection, although high rates of coinfection between COVID-19 and other respiratory pathogens are expected. To the best of our knowledge, this is the first study to examine COVID-19 infection in patients diagnosed with active or previously treated TB in Turkey. In this study, the aim was to examine the frequency of COVID-19 and the factors affecting the frequency of COVID-19 in patients with active or previously treated TB. Method(s): The population of the retrospective cohort type study consisted of patients with TB enrolled in the Elazig Tuberculosis Dispensary between January 2015 and April 2021. The TB-related data of the patients was obtained from the Public Health Management System Tuberculosis System, and the COVID-19 information was obtained from the COVID-19 Case Tracking System. The status of being alive or dead and the date of death if they were dead were obtained from the Central Population Management System. Result(s): 23.92% (n=105) of 439 patients with TB were COVID-19 cases. Advanced age, having at least one comorbid disease, and the presence of chronic pulmonary disease, diabetes mellitus, and heart disease increased the risk of developing COVID-19 in active or previously treated patients with TB. Conclusion(s): COVID-19 was detected more frequently in active or previously treated TB patients than in the general population. Within the scope of public health services implemented to prevent the spread of COVID-19 infection, priority should be given to the TB patient group and older people, especially those with comorbid chronic pulmonary disease, diabetes mellitus, and heart disease in this group. Copyright © 2022 by The Medical Bulletin of Istanbul Haseki Training and Research Hospital The Medical Bulletin of Haseki published by Galenos Yayinevi.

目的:关于冠状病毒病-2019 (COVID-19)和结核病(TB)合并感染的文献有限，尽管预计COVID-19与其他呼吸道病原体的合并感染率很高。据我们所知，这是首个在土耳其检查被诊断为活动性结核病或曾接受过治疗的结核病患者中COVID-19感染情况的研究。本研究旨在探讨活动性或既往治疗过的结核病患者中COVID-19的发病频率及其影响因素。方法:回顾性队列型研究的人群包括2015年1月至2021年4月在Elazig结核病药房登记的结核病患者。患者结核病相关数据来自公共卫生管理系统结核病系统，COVID-19信息来自COVID-19病例跟踪系统。他们的生死状况及死亡日期均由中央人口管理系统查询。结果:439例TB患者中有23.92% (n=105)为COVID-19病例。高龄、至少有一种合并症以及存在慢性肺病、糖尿病和心脏病增加了活动性或既往治疗过的结核病患者发生COVID-19的风险。结论:与一般人群相比，在活动性或既往治疗过的结核病患者中检测到COVID-19的频率更高。在为预防COVID-19感染传播而实施的公共卫生服务范围内，应优先考虑结核病患者群体和老年人，特别是这一群体中合并慢性肺病、糖尿病和心脏病的人群。伊斯坦布尔Haseki培训和研究医院医学公报版权所有©2022。Galenos Yayinevi出版的Haseki医学公报。

{"title":"Clinical Characteristics of COVID-19 in Active or Previously Treated Tuberculosis Patients in Turkey","authors":"Sumeyra Kayali, Fatma Nur Karaçorlu, Mustafa YILMAZ, Zulal Aşçı Toraman, E. Pirinççi","doi":"10.4274/haseki.galenos.2022.8327","DOIUrl":"https://doi.org/10.4274/haseki.galenos.2022.8327","url":null,"abstract":"Aim: There is limited literature on coronavirus disease-2019 (COVID-19) and tuberculosis (TB) coinfection, although high rates of coinfection between COVID-19 and other respiratory pathogens are expected. To the best of our knowledge, this is the first study to examine COVID-19 infection in patients diagnosed with active or previously treated TB in Turkey. In this study, the aim was to examine the frequency of COVID-19 and the factors affecting the frequency of COVID-19 in patients with active or previously treated TB. Method(s): The population of the retrospective cohort type study consisted of patients with TB enrolled in the Elazig Tuberculosis Dispensary between January 2015 and April 2021. The TB-related data of the patients was obtained from the Public Health Management System Tuberculosis System, and the COVID-19 information was obtained from the COVID-19 Case Tracking System. The status of being alive or dead and the date of death if they were dead were obtained from the Central Population Management System. Result(s): 23.92% (n=105) of 439 patients with TB were COVID-19 cases. Advanced age, having at least one comorbid disease, and the presence of chronic pulmonary disease, diabetes mellitus, and heart disease increased the risk of developing COVID-19 in active or previously treated patients with TB. Conclusion(s): COVID-19 was detected more frequently in active or previously treated TB patients than in the general population. Within the scope of public health services implemented to prevent the spread of COVID-19 infection, priority should be given to the TB patient group and older people, especially those with comorbid chronic pulmonary disease, diabetes mellitus, and heart disease in this group. Copyright © 2022 by The Medical Bulletin of Istanbul Haseki Training and Research Hospital The Medical Bulletin of Haseki published by Galenos Yayinevi.","PeriodicalId":42416,"journal":{"name":"Haseki TIp Bulteni-Medical Bulletin of Haseki","volume":"27 1","pages":""},"PeriodicalIF":0.3,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91184186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Diffuse Miliaria Cristalina due to Severe Hypernatremic Dehydration: A Neonatal Case Report with a Current Literature Review 严重高钠血症性脱水导致弥漫性水晶粟疹:1例新生儿病例报告及当前文献综述

IF 0.3 Q3 MEDICINE, GENERAL & INTERNAL

Haseki TIp Bulteni-Medical Bulletin of Haseki

Pub Date : 2022-11-01 DOI: 10.4274/haseki.galenos.2022.8612

B. Aydın, E. Botan

the patient, who was born by cesarean section at 39 weeks and 3200 g from a 30-year-old mother. It was learned that the sucking reflex of the patient decreased after the postnatal 10 th day, and there was a decrease in the amount of urine and the number of daily stools. The patient was admitted to the neonatal intensive care unit (NICU) with the diagnosis of severe dehydration.

这名患者在怀孕39周、体重3200公斤时，由一名30岁的母亲剖宫产。据了解，患者产后第10天吸吮反射减弱，尿量及日排便次数均有所减少。患者因严重脱水被送入新生儿重症监护病房(NICU)。

引用次数: 0

Evaluation of the Relationship Between Quality of Life, Serum 25 (OH) Vitamin D Levels, and Anxiety and Depression in Patients with Irritable Bowel Syndrome: A Case-Control Study 肠易激综合征患者生活质量、血清25 (OH)维生素D水平与焦虑和抑郁之间关系的评估:一项病例对照研究

IF 0.3 Q3 MEDICINE, GENERAL & INTERNAL

Haseki TIp Bulteni-Medical Bulletin of Haseki

Pub Date : 2022-11-01 DOI: 10.4274/haseki.galenos.2022.8419

Muharrem Bayrak, K. Çadırcı

引用次数: 0

Comparison of the Effects of Kinesio Taping Versus Dry Needling on Pain Intensity, Shoulder range of Motion, and upper Limb Function in Patients with Myofascial Pain Syndrome in the Trapezius Muscle: A Randomized Controlled Trial 肌内效贴贴与干针对斜方肌肌筋膜疼痛综合征患者疼痛强度、肩关节活动度和上肢功能影响的比较:一项随机对照试验

IF 0.3 Q3 MEDICINE, GENERAL & INTERNAL

Haseki TIp Bulteni-Medical Bulletin of Haseki

Pub Date : 2022-11-01 DOI: 10.4274/haseki.galenos.2022.8467

Abdurrahim Yildiz, R. Mustafaoglu, Ş. Dinçer, O. B. Gozubuyuk, G. Metin

引用次数: 0

Evaluating the Information Content, Readability, and Reliability of Turkish Websites about Fibromyalgia 评估土耳其网站关于纤维肌痛的信息内容、可读性和可靠性

IF 0.3 Q3 MEDICINE, GENERAL & INTERNAL

Haseki TIp Bulteni-Medical Bulletin of Haseki

Pub Date : 2022-11-01 DOI: 10.4274/haseki.galenos.2022.8737

Ramazan Yılmaz, Savaş Karpuz, H. H. Gokpinar, H. Yılmaz

引用次数: 1

Association Between Cerebral Small Vessel Disease and Intracranial Arterial Calcification 脑血管疾病与颅内动脉钙化的关系

IF 0.3 Q3 MEDICINE, GENERAL & INTERNAL

Haseki TIp Bulteni-Medical Bulletin of Haseki

Pub Date : 2022-11-01 DOI: 10.4274/haseki.galenos.2022.8449

Cansu Ozturk, O. Gungor

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Haseki TIp Bulteni-Medical Bulletin of Haseki

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀